| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 84601 |
DOTA–Bipy–RuII配位共轭物 |
308 |
h |
2024-12-19 |
| 84602 |
cas:1007215-91-9，1-(4-formylphenyl)-1-oxo-5,8,11-trioxa-2-azatridecan-13-oic acid |
184 |
zyl |
2024-12-19 |
| 84603 |
DOTA-cT84.66 DOTA偶联单克隆抗体cT84.66 |
161 |
h |
2024-12-19 |
| 84604 |
DOTA-Ahx-(D-Lys(6)-GnRH1)金属螯合剂DOTA偶联氨基己酸缀合D-赖氨酸 |
172 |
h |
2024-12-19 |
| 84605 |
DOTA-LRB 2-(6-(二乙基氨基)-3-(二乙基亚胺基)-3H-呫吨-9-基)-5-(N-(2-(2-(4,7,10-三(羧甲基)-1,4,7,10-四氮杂环十二烷-1-基)乙酰胺基 |
178 |
h |
2024-12-19 |
| 84606 |
DOTA-Y3-TATE DOTA偶联激动剂Y3-TATE |
199 |
h |
2024-12-19 |
| 84607 |
DOTA-2-脱氧-D-氨基葡萄糖 DOTA-DG |
207 |
h |
2024-12-19 |
| 84608 |
DOTA-c(RGDfK)DOTA偶联环肽 |
148 |
h |
2024-12-19 |
| 84609 |
SCN-DOTA-PCA DOTA-苯甲酰胺衍生物 |
191 |
h |
2024-12-19 |
| 84610 |
DOTA-N-羟基琥珀酰亚胺 DOTA-N-hydroxysuccinimide |
174 |
h |
2024-12-19 |
| 84611 |
低分子量CLT1肽靶向Gd(III)螯合物CLT1-dL-(Gd-DOTA) |
257 |
h |
2024-12-19 |
| 84612 |
DOTA-1,2-二硬脂酰-sn-甘油-3-磷酸乙醇胺脂质 |
236 |
h |
2024-12-19 |
| 84613 |
1,4,7-三氮杂环壬烷-1,4,7-三乙酸(NOTA17,19) |
179 |
h |
2024-12-19 |
| 84614 |
cas:1061569-06-9，4-formyl-N-(2-(2-hydroxyethoxy)ethyl)benzamide ADC抗体偶联药物 |
141 |
zyl |
2024-12-19 |
| 84615 |
DBCO-PEG4-VA-PBD，2241644-09-5，ADC定制 |
129 |
wyh |
2024-12-19 |
| 84616 |
Val-Cit-PAB-MMAE，cas:644981-35-1，ADC定制 |
168 |
wyh |
2024-12-19 |
| 84617 |
DOTA-GMSH 1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸(DOTA)偶联α-黑素细胞刺激素(α-MSH)类似物 |
222 |
h |
2024-12-19 |
| 84618 |
mDPR-Val-Cit-PAB-MMAE，1491152-26-1，ADC定制 |
141 |
wyh |
2024-12-19 |
| 84619 |
G3-(Gd-DTPA)(24)DOTA-钆(Gd)大分子造影剂 |
355 |
h |
2024-12-19 |
| 84620 |
DOTA-多柔比星 DOTA-DOX |
190 |
h |
2024-12-19 |
| 84621 |
聚(HPMA)-c(RGDyK)-DOTA |
129 |
h |
2024-12-19 |
| 84622 |
1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸(DOTA)螯合剂共轭的应变环辛烯衍生物二苄基环辛烯(DBCO) |
167 |
h |
2024-12-19 |
| 84623 |
PDDEC-NB；2-methyl-2-(pyridin-2-yldisulfanyl)propyl 4-nitrophenyl carbonate |
127 |
zyl |
2024-12-19 |
| 84624 |
(67)Ga-DOTA复合物共轭二膦酸盐(67)Ga-DOTA-Bn-SCN-HBP |
202 |
h |
2024-12-19 |
| 84625 |
MWCNT/PEI-FI-DOTA(Gd)-PEG 异硫氰酸荧光素(FI)和钆(Gd)螯合剂共价接枝聚乙烯亚胺修饰的多壁碳纳米管 |
193 |
h |
2024-12-19 |
| 84626 |
DOTA-Cys-hAb47 螯合剂DOTA偶联半胱氨酸-抗EphB4抗体hAb47和hAb131 |
241 |
h |
2024-12-19 |
| 84627 |
1,4,7,10-四氮杂环十二烷-N,N,N,N-四乙酸(DOTA)-F(ab)2-曲妥珠单抗 |
236 |
h |
2024-12-19 |
| 84628 |
DOTA-MG11(DOTA-DGlu-Ala-Tyr-Gly-Trp-Met-Asp)DOTA肽缀合物 |
268 |
h |
2024-12-19 |
| 84629 |
AcLys-PABC-VC-Aur0101， cas:1438851-17-2，ADC定制 |
213 |
wyh |
2024-12-19 |
| 84630 |
cas:107348-47-0，2,5-dioxopyrrolidin-1-yl 3-(pyridin-2-yldisulfanyl)butanoate ADC抗体偶联药物 |
149 |
zyl |
2024-12-19 |
| 84631 |
SMCC-DM4 ， cas:1228105-52-9，ADC定制 |
134 |
wyh |
2024-12-19 |
| 84632 |
cas:1639939-40-4 Mal-Val-Ala-PAB-PNP |
156 |
zyl |
2024-12-19 |
| 84633 |
MA-PEG8-VA-PAB-SG3199，ADC定制 |
272 |
wyh |
2024-12-19 |
| 84634 |
Acid-PEG4-Val-Cit-PAB-MMAE |
147 |
zyl |
2024-12-19 |
| 84635 |
MC-Val-Cit-PAB-Indibulin，cas:2055896-95-0，ADC定制 |
142 |
wyh |
2024-12-19 |
| 84636 |
cas:1096584-62-1 Mal-Val-Cit-PAB-PNP |
143 |
zyl |
2024-12-19 |
| 84637 |
cas:863971-53-3 Fmoc-Val-Cit-PAB-PNP |
151 |
zyl |
2024-12-19 |
| 84638 |
MC-Sq-Cit-PAB-Dolastatin10 ，cas:1941168-65-5，ADC定制 |
165 |
wyh |
2024-12-19 |
| 84639 |
Mal-PEG2-Val-Cit-PAB-OH ADC抗体偶联药物 |
146 |
zyl |
2024-12-19 |
| 84640 |
N3-PEG4-DYKDDDD-Doxorubicin，ADC定制 |
160 |
wyh |
2024-12-19 |
| 84641 |
MA-vc-PAB-DM1 cas:1464051-44-2 |
117 |
zyl |
2024-12-19 |
| 84642 |
DBCO-PEG4-VC-PAB-DMAE-Duocarmycin SA |
187 |
zyl |
2024-12-19 |
| 84643 |
VC-PAB-DMAE-PNU159682 ADC抗体偶联药物 |
145 |
zyl |
2024-12-19 |
| 84644 |
MC-GGFG-DX8951 cas:1600418-29-8 |
128 |
zyl |
2024-12-19 |
| 84645 |
DOTA-NGR NGR肽偶联1,4,7,10-四氮杂环十二烷-N,N’,N”,N”’-四乙酸(DOTA) |
169 |
h |
2024-12-19 |
齐岳微信公众号
官方微信
库存查询